Barclays PLC Fulcrum Therapeutics, Inc. Transaction History
Barclays PLC
- $377 Billion
- Q3 2024
A detailed history of Barclays PLC transactions in Fulcrum Therapeutics, Inc. stock. As of the latest transaction made, Barclays PLC holds 124,141 shares of FULC stock, worth $482,908. This represents 0.0% of its overall portfolio holdings.
Number of Shares
124,141
Previous 124,141
-0.0%
Holding current value
$482,908
Previous $443,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding FULC
# of Institutions
149Shares Held
51.9MCall Options Held
6.91MPut Options Held
1.89M-
Ra Capital Management, L.P. Boston, MA10.2MShares$39.8 Million0.51% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA5.25MShares$20.4 Million2.43% of portfolio
-
Black Rock Inc. New York, NY4.8MShares$18.7 Million0.0% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT4.78MShares$18.6 Million1.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.27MShares$12.7 Million0.0% of portfolio
About Fulcrum Therapeutics, Inc.
- Ticker FULC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,038,900
- Market Cap $202M
- Description
- Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystro...